5 Key Takeaways
-
1
CAR T cell administration before glioblastoma surgery improved tumor control and survival in mouse models compared to postoperative treatment.
-
2
Surgery-induced changes in the tumor microenvironment may hinder the effectiveness of postoperative immunotherapy.
-
3
The study found increased TREM2 levels around the resection cavity, indicating immunosuppressive myeloid cell activity post-surgery.
-
4
Preoperative CAR T cells maintained stronger effector function and better distribution compared to those administered during surgery.
-
5
The Geneva research team plans to initiate a phase I trial testing CAR T cells in newly diagnosed glioblastoma patients.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
